期刊
HUMAN GENE THERAPY
卷 26, 期 3, 页码 134-144出版社
MARY ANN LIEBERT, INC
DOI: 10.1089/hum.2014.069
关键词
-
资金
- University of Helsinki
- Marie Curie FP7-PEOPLE-IRG
- K. Albin Johanssons Stiftelse
- ASCO Foundation
- HUCH Research Funds (EVO)
- Sigrid Juselius Foundation
- Academy of Finland
- Biocentrum Helsinki
- Biocenter Finland
- Finnish Cancer Organizations
- Finnish Cultural Foundation
- Emil Aaltonen Foundation
- Waldemar von Frenckell Foundation
For long it has been recognized that tumor necrosis factor alpha (TNFa) has anticancer characteristics, and its use as a cancer therapeutic was proposed already in the 1980s. However, its systemic toxicity has limited its usability. Oncolytic viruses, selectively cancer-killing viruses, have shown great potency, and one of their most useful aspects is their ability to produce high amounts of transgene products locally, resulting in high local versus systemic concentrations. Therefore, the overall magnitude of tumor cell killing results from the combination of oncolysis, transgene-mediated direct effect such as TNFa-mediated apoptosis, and, perhaps most significantly, from activation of the host immune system against the tumor. We generated a novel chimeric oncolytic adenovirus expressing human TNFa, Ad5/3-D24-hTNFa, whose efficacy and immunogenicity were tested in vitro and in vivo. The hTNFa-expressing adenovirus showed increased cancer-eradicating potency, which was shown to be because of elevated apoptosis and necrosis rates and induction of various immune responses. Interestingly, we saw increase in immunogenic cell death markers in Ad5/3-d24-hTNFa-treated cells. Moreover, tumors treated with Ad5/3-D24-hTNFa displayed enhanced presence of OVA-specific cytotoxic T cells. We thus can conclude that tumor eradication and antitumor immune responses mediated by Ad5/3-d24-hTNFa offer a new potential drug candidate for cancer therapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据